ArticleInternational journal of cancer2018
Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus.
Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Circulating genotypes of human papillomavirus in adult women of reproductive age from the Boeny region of Madagascar: a cross-sectional study to explore needs and opportunities for HPV vaccination in the country.BMC infectious diseases · 2026Article
- Prevalence of the most common types of high-risk HPV and p16Postepy dermatologii i alergologii · 2026Article
- Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countries.EClinicalMedicine · 2024Article
- Perceptions and acceptability of HPV vaccination among parents of female adolescents 9-14 in China: A cross-sectional survey based on the theory of planned behavior.Human vaccines & immunotherapeutics · 2023Article
- Stagnation or safety? Reassessment of the human papillomavirus vaccination dosing regimen in Japan.Therapeutic advances in vaccines and immunotherapy · 2023Article
- Prevention of Cervical Cancer in Low-Resource African Settings.Obstetrics and gynecology clinics of North America · 2022Review
- Discrepancy of human papillomavirus vaccine uptake and intent between girls 9-14 and their mothers in a pilot region of Shanghai, China.Human vaccines & immunotherapeutics · 2022Article
- Projections of human papillomavirus (HPV) vaccination impact in Ethiopia, India, Nigeria and Pakistan: a comparative modelling study.BMJ global health · 2021Article
- Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world.eLife · 2021Article
- National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects.Preventive medicine · 2021Review
- Vaccine hesitancy : Report of a student study group.Wiener klinische Wochenschrift · 2020Review
- Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study.The Lancet. Global health · 2020Article
- Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.Lancet (London, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Up to 2016, low- and middle-income countries mostly introduced routine human papillomavirus (HPV) vaccination for just a single age-cohort of girls each year. However, high-income countries have reported large reductions in HPV prevalence following "catch-up" vaccination of multiple age-cohorts in the year of HPV vaccine introduction. We used the mathematical model PRIME to project the incremental impact of vaccinating 10- to 14-year-old girls compared to routine HPV vaccination only in the same year that routine vaccination is expected to be introduced for 9-year-old girls across 73 low- and lower-middle-income countries. Adding multiple age-cohort vaccination could increase the number of cervical cancer deaths averted by vaccine introductions in 2015-2030 by 30-40% or an additional 1.23-1.79 million over the lifetime of the vaccinated cohorts. The number of girls needed to vaccinate to prevent one death is 101 in the most pessimistic scenario, which is only slightly greater than that for routine vaccination of 9-year-old girls (87). These results hold even when assuming that girls who have sexually debuted do not benefit from vaccination. Results suggest that multiple age-cohort vaccination of 9- to 14-year-old girls could accelerate HPV vaccine impact and be cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.